You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 23, December 15, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cholinergic Markers in Alzheimer Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: It has been nearly 20 years since the inception and integration of the cholinergic hypothesis,1 the only approach that has so far produced drugs approved for treating Alzheimer disease (AD). The study by Dr Davis and colleagues2 is the first attempt to explore the temporal relationship between progressive declines in key cholinergic markers and memory in AD. The authors report that choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities remain normal until the late stages of AD and suggest that the link between cholinergic dysfunction and the onset of the characteristic symptoms is therefore weak. However, caution must be exercised when interpreting data using ChAT and AChE as markers of cholinergic function.

Neither ChAT nor AChE is rate-limiting, and therefore they do not reflect cholinergic function.3 In fact, ChAT can be inhibited up to 90% with no measurable effects on acetylcholine synthesis or release. At the same time, . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Kenneth L. Davis, Richard C. Mohs, Deborah Marin, Dushyant P. Purohit, Daniel P. Perl, Melinda Lantz, Gregory Austin, and Vahram Haroutunian
JAMA. 1999;281(15):1401-1406.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radiation Dosimetry of {beta}-Amyloid Tracers 11C-PiB and 18F-BAY94-9172
O'Keefe et al.
JNM 2009;50:309-315.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.